This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
intensive care | 5268 |
critically ill | 3390 |
care unit | 2939 |
mechanical ventilation | 2712 |
ill patients | 2465 |
critical care | 2226 |
icu admission | 1920 |
septic shock | 1806 |
acute respiratory | 1677 |
icu patients | 1559 |
patients admitted | 1525 |
risk factors | 1425 |
respiratory failure | 1150 |
hospital mortality | 1000 |
respiratory distress | 981 |
cardiac arrest | 977 |
mean age | 956 |
mortality rate | 948 |
icu stay | 910 |
brain injury | 857 |
distress syndrome | 835 |
two groups | 827 |
severe sepsis | 796 |
organ failure | 777 |
apache ii | 768 |
coronavirus disease | 764 |
cohort study | 751 |
care units | 750 |
mechanically ventilated | 729 |
mg kg | 714 |
blood pressure | 693 |
control group | 673 |
observational study | 671 |
health care | 670 |
emergency department | 664 |
statistically significant | 662 |
acquired pneumonia | 658 |
significantly higher | 647 |
logistic regression | 633 |
systematic review | 609 |
critical illness | 603 |
study period | 588 |
adult patients | 583 |
severe acute | 569 |
author funder | 563 |
granted medrxiv | 563 |
significant difference | 557 |
among patients | 539 |
hospitalized patients | 533 |
ventilated patients | 530 |
copyright holder | 524 |
university hospital | 519 |
hospital stay | 516 |
patients undergoing | 515 |
respiratory syndrome | 515 |
trauma patients | 515 |
retrospective study | 513 |
traumatic brain | 512 |
patients receiving | 509 |
cardiac surgery | 508 |
lung injury | 507 |
icu beds | 504 |
patients received | 501 |
version posted | 499 |
novel coronavirus | 499 |
ng ml | 494 |
associated pneumonia | 494 |
ml kg | 486 |
one patient | 476 |
patients treated | 473 |
day mortality | 460 |
significant differences | 455 |
clinical characteristics | 450 |
prospective study | 448 |
risk factor | 446 |
respiratory tract | 445 |
high risk | 444 |
doc id | 440 |
cord uid | 440 |
patients without | 439 |
organ dysfunction | 438 |
united states | 437 |
septic patients | 433 |
sofa score | 432 |
mortality rates | 430 |
renal failure | 423 |
antibiotic therapy | 422 |
present study | 419 |
median age | 417 |
years old | 414 |
kidney injury | 411 |
made available | 409 |
ii score | 409 |
clinical practice | 408 |
care medicine | 408 |
blood flow | 407 |
icu mortality | 402 |
severe covid | 397 |
poor outcome | 393 |
increased risk | 393 |
acute kidney | 393 |
factors associated | 388 |
two patients | 381 |
within hours | 378 |
neurocritical care | 378 |
hospital discharge | 377 |
randomized controlled | 376 |
subarachnoid hemorrhage | 374 |
pao fio | 373 |
renal replacement | 373 |
arterial pressure | 369 |
statistical analysis | 367 |
inflammatory response | 367 |
central venous | 366 |
heart rate | 364 |
consecutive patients | 363 |
multivariate analysis | 362 |
international license | 359 |
mg dl | 359 |
tidal volume | 357 |
replacement therapy | 356 |
cardiac output | 354 |
pg ml | 351 |
clinical outcomes | 350 |
controlled trial | 347 |
significantly lower | 343 |
regression analysis | 342 |
heart failure | 334 |
primary outcome | 333 |
arterial blood | 333 |
performed using | 331 |
adverse events | 330 |
ct scan | 322 |
hospital admission | 321 |
least one | 321 |
inclusion criteria | 321 |
patients requiring | 319 |
peer review | 316 |
included patients | 316 |
multiple organ | 315 |
infection control | 313 |
ischemic stroke | 307 |
clinical trials | 306 |
clinical trial | 306 |
public health | 306 |
prospective observational | 303 |
staphylococcus aureus | 303 |
blood samples | 303 |
retrospective cohort | 302 |
high mortality | 298 |
mean arterial | 298 |
invasive mechanical | 293 |
oxygen saturation | 292 |
informed consent | 292 |
respiratory rate | 292 |
infectious diseases | 286 |
ards patients | 284 |
icu discharge | 283 |
reactive protein | 281 |
higher mortality | 280 |
clinical course | 279 |
nosocomial infections | 278 |
saps ii | 274 |
status epilepticus | 274 |
intracranial pressure | 274 |
patient care | 273 |
within days | 272 |
medrxiv preprint | 272 |
increased mortality | 272 |
palliative care | 269 |
first hours | 268 |
clinical features | 268 |
independently associated | 267 |
infected patients | 264 |
membrane oxygenation | 264 |
blood cultures | 261 |
icu length | 261 |
elderly patients | 257 |
significantly associated | 255 |
year period | 254 |
icu care | 254 |
body weight | 254 |
predictive value | 253 |
odds ratio | 253 |
pulmonary disease | 253 |
patients hospitalized | 252 |
invasive ventilation | 252 |
glasgow coma | 252 |
extracorporeal membrane | 252 |
social distancing | 248 |
airway pressure | 248 |
syndrome coronavirus | 244 |
lower respiratory | 242 |
retrospective analysis | 242 |
patients died | 241 |
three patients | 241 |
acute lung | 241 |
patients presenting | 238 |
medical center | 238 |
ethics regulations | 238 |
severe disease | 237 |
sample size | 236 |
kidney disease | 234 |
first days | 234 |
pulmonary embolism | 232 |
functional outcome | 231 |
long term | 229 |
previous studies | 226 |
data collection | 225 |
clinical data | 225 |
brain death | 225 |
higher risk | 225 |
case report | 224 |
overall mortality | 222 |
care patients | 220 |
exclusion criteria | 218 |
computed tomography | 217 |
univariate analysis | 216 |
per patient | 216 |
medical records | 212 |
prospective cohort | 212 |
four patients | 212 |
may also | 211 |
mm hg | 211 |
interquartile range | 210 |
month period | 210 |
myocardial infarction | 210 |
case series | 209 |
blood gas | 209 |
platelet count | 208 |
surgical patients | 208 |
icu admissions | 208 |
chronic obstructive | 207 |
pseudomonas aeruginosa | 207 |
therapeutic hypothermia | 207 |
confidence interval | 207 |
healthcare workers | 206 |
intracerebral hemorrhage | 203 |
pulmonary artery | 203 |
acute renal | 203 |
family members | 203 |
tertiary care | 203 |
patients may | 202 |
per day | 202 |
baseline characteristics | 201 |
blood glucose | 201 |
ml min | 200 |
vital signs | 199 |
respiratory support | 198 |
year old | 198 |
coma scale | 197 |
prone positioning | 196 |
demographic data | 196 |
decision making | 196 |
spontaneous breathing | 196 |
cancer patients | 196 |
rights reserved | 196 |
significant increase | 195 |
antibiotic treatment | 195 |
regression model | 193 |
determine whether | 193 |
obstructive pulmonary | 193 |
pressure support | 193 |
disease severity | 192 |
plasma levels | 192 |
independent risk | 191 |
nitric oxide | 191 |
total number | 191 |
median time | 190 |
patients infected | 190 |
antimicrobial therapy | 190 |
age years | 189 |
patients underwent | 189 |
side effects | 188 |
significantly different | 187 |
ventilatory support | 187 |
commonly used | 187 |
five patients | 186 |
patient population | 186 |
data suggest | 186 |
severe ards | 186 |
acute phase | 185 |
world health | 185 |
hospital length | 184 |
oxygen therapy | 183 |
pilot study | 183 |
chart review | 182 |
patient outcomes | 181 |
chain reaction | 181 |
standard deviation | 181 |
significantly increased | 180 |
blood culture | 180 |
statistical significance | 180 |
group i | 179 |
renal function | 178 |
cerebral edema | 178 |
average age | 177 |
acute physiology | 177 |
collected data | 177 |
cardiac index | 177 |
failure assessment | 176 |
polymerase chain | 175 |
thoracic surgery | 175 |
kg min | 175 |
trauma center | 175 |
neurological outcome | 175 |
head injury | 175 |
fluid responsiveness | 174 |
study group | 174 |
endotracheal tube | 173 |
clinical outcome | 172 |
enteral nutrition | 171 |
pandemic influenza | 171 |
health organization | 171 |
symptom onset | 170 |
controlled trials | 170 |
urinary tract | 170 |
acute care | 169 |
protective equipment | 169 |
study population | 169 |
bronchoalveolar lavage | 169 |
patients required | 168 |
coronary artery | 168 |
ethics committee | 168 |
injury severity | 168 |
emergency medicine | 168 |
fluid balance | 167 |
fio ratio | 166 |
nosocomial infection | 165 |
blood loss | 165 |
diabetes mellitus | 165 |
patients included | 164 |
requiring icu | 163 |
medical icu | 162 |
shock patients | 162 |
risk patients | 162 |
severity score | 162 |
severe tbi | 161 |
tbi patients | 160 |
hand hygiene | 160 |
bone marrow | 160 |
immune response | 160 |
blood transfusion | 159 |
neuromuscular blockade | 159 |
results suggest | 159 |
cardiogenic shock | 159 |
machine learning | 159 |
cognitive impairment | 158 |
personal protective | 158 |
care workers | 157 |
transplant recipients | 157 |
measured using | 156 |
may lead | 156 |
gas exchange | 156 |
survival rate | 155 |
seven patients | 155 |
prognostic factors | 155 |
atrial fibrillation | 154 |
hospital cardiac | 154 |
exact test | 154 |
surgical icu | 154 |
signifi cant | 154 |
heart disease | 153 |
randomized clinical | 153 |
blood cell | 153 |
infectious disease | 153 |
poor prognosis | 153 |
patient characteristics | 152 |
left ventricular | 152 |
data analysis | 152 |
virus infection | 151 |
icu los | 151 |
analyzed using | 151 |
lactate levels | 151 |
nervous system | 150 |
six patients | 150 |
tract infections | 150 |
liver transplantation | 150 |
linear regression | 150 |
systemic inflammatory | 150 |
observational studies | 150 |
tract infection | 150 |
serum creatinine | 149 |
adverse effects | 149 |
endotracheal intubation | 149 |
analysis showed | 148 |
continuous variables | 148 |
venous thromboembolism | 148 |
influenza virus | 147 |
abdominal pain | 147 |
life support | 147 |
pulmonary edema | 147 |
teaching hospital | 146 |
streptococcus pneumoniae | 145 |
old male | 145 |
nursing staff | 145 |
assessed using | 145 |
intubated patients | 145 |
noninvasive ventilation | 145 |
high dose | 145 |
pediatric patients | 144 |
injured patients | 144 |
randomized trial | 143 |
sequential organ | 143 |
compared using | 143 |
age group | 142 |
lung disease | 142 |
single center | 142 |
intracranial hemorrhage | 142 |
body mass | 141 |
prospectively collected | 141 |
expiratory pressure | 141 |
multicenter study | 141 |
severe respiratory | 140 |
cardiac injury | 140 |
significantly reduced | 140 |
one year | 140 |
antibiotic resistance | 139 |
blood gases | 139 |
age groups | 139 |
secondary outcomes | 139 |
observational cohort | 139 |
fi rst | 139 |
icu bed | 138 |
acute brain | 138 |
significant reduction | 138 |
obese patients | 138 |
good outcome | 137 |
prone position | 137 |
study included | 137 |
th day | 137 |
healthy volunteers | 137 |
positive patients | 136 |
surgical intervention | 136 |
middle east | 136 |
may help | 136 |
brain tissue | 135 |
practice guidelines | 135 |
respiratory viruses | 135 |
intracranial hypertension | 134 |
study conducted | 134 |
red blood | 134 |
patients showed | 133 |
mortality among | 133 |
acute ischemic | 133 |
peripheral blood | 133 |
health system | 132 |
liver disease | 132 |
medical history | 132 |
significant correlation | 132 |
surgical procedures | 132 |
surgical treatment | 131 |
mental status | 131 |
pediatric intensive | 131 |
posted june | 131 |
new york | 131 |
mass index | 131 |
icu nurses | 130 |
three groups | 129 |
one case | 129 |
serum levels | 129 |
signifi cantly | 129 |
fluid resuscitation | 128 |
eight patients | 128 |
categorical variables | 128 |
necrosis factor | 128 |
bacterial infection | 128 |
square test | 127 |
may result | 127 |
whole blood | 127 |
severe cap | 127 |
patients developed | 127 |
authors declare | 127 |
important role | 126 |
postoperative period | 126 |
systolic blood | 126 |
mean duration | 126 |
parenteral nutrition | 126 |
previously reported | 125 |
general population | 125 |
disease control | 125 |
time points | 125 |
east respiratory | 125 |
myocardial injury | 125 |
head ct | 124 |
significant decrease | 124 |
respiratory infection | 124 |
continuous infusion | 124 |
multivariate logistic | 124 |
surviving sepsis | 124 |
oxygen delivery | 124 |
stroke volume | 124 |
retrospective observational | 123 |
soft tissue | 123 |
urine output | 123 |
severe cases | 122 |
cmv reactivation | 122 |
one hundred | 122 |
physical examination | 122 |
retrospective review | 122 |
data collected | 122 |
widely used | 122 |
patient safety | 122 |
large number | 122 |
quality improvement | 122 |
patients aged | 121 |
aneurysmal subarachnoid | 121 |
confirmed cases | 121 |
emergency room | 121 |
liver failure | 121 |
lymphocyte count | 121 |
medical staff | 121 |
airway management | 121 |
care services | 121 |
clinical findings | 121 |
receiver operating | 120 |
lg ml | 120 |
respiratory infections | 120 |
cardiovascular disease | 120 |
scoring system | 120 |
endothelial cells | 119 |
may improve | 119 |
treated patients | 119 |
corticosteroid therapy | 119 |
group ii | 119 |
icu staff | 118 |
severely ill | 118 |
positive end | 118 |
ct scans | 117 |
ill patient | 117 |
central nervous | 117 |
viral infections | 117 |
confirmed covid | 117 |
posted may | 117 |
independent predictor | 117 |
bacterial pneumonia | 117 |
severe traumatic | 117 |
clinically relevant | 117 |
escherichia coli | 117 |
electronic medical | 116 |
sepsis campaign | 116 |
see table | 116 |
chest pain | 116 |
surgery patients | 116 |
convalescent plasma | 116 |
stem cell | 116 |
requiring mechanical | 116 |
even though | 116 |
prognostic value | 116 |
identify patients | 115 |
gold standard | 115 |
medical intensive | 115 |
patients suffering | 115 |
retrospective chart | 115 |
many patients | 114 |
ill covid | 114 |
poor outcomes | 114 |
general hospital | 114 |
prolonged mechanical | 114 |
clinical signs | 113 |
patients presented | 113 |
median duration | 113 |
clinical studies | 113 |
nine patients | 113 |
hemodynamic instability | 113 |
carbon dioxide | 113 |
confidence intervals | 113 |
care system | 113 |
cerebral perfusion | 112 |
old man | 112 |
mental health | 112 |
stroke patients | 112 |
cerebral blood | 112 |
ill adults | 112 |
two different | 112 |
common cause | 112 |
crit care | 112 |
recent studies | 112 |
glasgow outcome | 111 |
primary endpoint | 111 |
pulmonary hypertension | 111 |
cytokine storm | 111 |
older age | 111 |
white blood | 111 |
cardiopulmonary resuscitation | 111 |
cerebral ischemia | 111 |
leading cause | 110 |
table shows | 110 |
tidal volumes | 110 |
early diagnosis | 110 |
mortality risk | 110 |
invasive aspergillosis | 110 |
hemorrhagic shock | 110 |
two cases | 110 |
study aimed | 109 |
body temperature | 109 |
viral load | 109 |
tumor necrosis | 109 |
icu survivors | 109 |
free days | 109 |
operating room | 109 |
kg day | 109 |
high levels | 109 |
bloodstream infections | 109 |
study showed | 109 |
high incidence | 109 |
study design | 109 |
partial pressure | 108 |
emergency surgery | 108 |
flow nasal | 108 |
cardiopulmonary bypass | 108 |
respiratory system | 107 |
emergency departments | 107 |
higher rate | 107 |
care setting | 107 |
viral infection | 107 |
ill children | 107 |
healthcare professionals | 107 |
clinical presentation | 107 |
hemodynamic parameters | 106 |
combination therapy | 106 |
functional status | 106 |
severity scores | 106 |
several studies | 106 |
negative predictive | 106 |
icu capacity | 106 |
antibiotic use | 105 |
intervention group | 105 |
ed patients | 105 |
icu group | 105 |
head trauma | 105 |
cell count | 105 |
venous catheter | 105 |
one week | 104 |
positive blood | 104 |
respiratory disease | 104 |
high level | 104 |
patients will | 104 |
copd patients | 104 |
united kingdom | 104 |
pulmonary vascular | 104 |
admitted patients | 104 |
nasal cannula | 104 |
care med | 103 |
modified rankin | 103 |
descriptive study | 103 |
clinical isolates | 103 |
chronic health | 103 |
mean time | 103 |
acute pancreatitis | 102 |
fl uid | 102 |
older adults | 102 |
medical care | 102 |
supplementary material | 102 |
missing data | 101 |
abdominal surgery | 101 |
last years | 101 |
chronic kidney | 101 |
may contribute | 101 |
first day | 101 |
vascular resistance | 101 |
center study | 101 |
blood cells | 100 |
severe head | 100 |
ii scores | 100 |
inflammatory cytokines | 100 |
days post | 100 |
small bowel | 100 |
preliminary results | 100 |
hospital beds | 100 |
one study | 100 |
sofa scores | 99 |
sah patients | 99 |
adult icu | 99 |
normal range | 99 |
without permission | 99 |
retrospectively reviewed | 99 |
reuse allowed | 98 |
per year | 98 |
level i | 98 |
roc curve | 98 |
older patients | 98 |
blood products | 98 |
review board | 98 |
viral pneumonia | 98 |
future studies | 98 |
enrolled patients | 98 |
allowed without | 98 |
ten patients | 98 |
positive airway | 98 |
study protocol | 97 |
immunocompromised patients | 97 |
unit patients | 97 |
gene expression | 97 |
elective surgery | 97 |
right ventricular | 97 |
significantly decreased | 97 |
calculated using | 97 |
real time | 97 |
medical record | 97 |
institutional review | 97 |
support ventilation | 97 |
enteral feeding | 97 |
higher incidence | 97 |
additional file | 97 |
systemic inflammation | 96 |
acinetobacter baumannii | 96 |
venous blood | 96 |
time period | 96 |
postoperative complications | 96 |
previously described | 95 |
pregnant women | 95 |
general icu | 95 |
icu team | 95 |
negative bacteria | 95 |
severe influenza | 95 |
task force | 95 |
liver injury | 95 |
outcome data | 95 |
patient outcome | 95 |
severe pneumonia | 95 |
tracheal intubation | 94 |
term outcomes | 94 |
metabolic acidosis | 94 |
icu setting | 94 |
resistant staphylococcus | 94 |
infectious complications | 94 |
severe community | 94 |
negative pressure | 94 |
outcome scale | 94 |
lower mortality | 94 |
chest radiograph | 94 |
fatality rate | 94 |
less likely | 93 |
descriptive statistics | 93 |
physiology score | 93 |
independent predictors | 93 |
multivariable logistic | 92 |
time spent | 92 |
hypoxemic respiratory | 92 |
determined using | 92 |
cerebrospinal fluid | 92 |
simplified acute | 92 |
surgical intensive | 92 |
patient data | 92 |
organ donation | 92 |
time pcr | 92 |
health evaluation | 92 |
hiv infection | 92 |
nosocomial pneumonia | 92 |
identified patients | 92 |
spinal cord | 92 |
general anesthesia | 91 |
clinically significant | 91 |
control measures | 91 |
general surgery | 91 |
nutritional support | 91 |
outcome measures | 91 |
immune system | 91 |
including patients | 91 |
surge capacity | 91 |
three different | 91 |
operating characteristic | 91 |
arrest patients | 91 |
results indicate | 91 |
significant improvement | 90 |
increased significantly | 90 |
required mechanical | 90 |
antimicrobial resistance | 90 |
current study | 90 |
test results | 90 |
cerebral artery | 90 |
remains unclear | 90 |
cause mortality | 90 |
clinical management | 90 |
healthy controls | 90 |
regression models | 90 |
medical conditions | 90 |
study including | 89 |
success rate | 89 |
antimicrobial agents | 89 |
thoracic society | 89 |
findings suggest | 89 |
included studies | 89 |
major cause | 89 |
cfu ml | 89 |
coronavirus pneumonia | 89 |
oxygen consumption | 89 |
saudi arabia | 89 |
flow oxygen | 88 |
underlying disease | 88 |
bacterial infections | 88 |
high prevalence | 88 |
illness severity | 88 |
three days | 87 |
data regarding | 87 |
case reports | 87 |
animal models | 87 |
every hours | 87 |
available data | 87 |
lung transplantation | 87 |
study shows | 87 |
inflammatory mediators | 87 |
infection rate | 87 |
major trauma | 87 |
continuous renal | 87 |
ejection fraction | 87 |
statistical analyses | 86 |
significant association | 86 |
venous pressure | 86 |
old female | 86 |
influenza infection | 86 |
community acquired | 86 |
respiratory syncytial | 86 |
european society | 86 |
working group | 86 |
clinical decision | 86 |
acute myocardial | 86 |
demographic characteristics | 85 |
chest ct | 85 |
randomized trials | 85 |
prospective studies | 85 |
control study | 85 |
gram negative | 85 |
ed visits | 85 |
predictive factors | 85 |
syncytial virus | 85 |
patients diagnosed | 85 |
excluded patients | 85 |
low dose | 85 |
tertiary hospital | 85 |
limited settings | 85 |
selected patients | 85 |
hypertonic saline | 85 |
first week | 85 |
ich patients | 85 |
response syndrome | 85 |
pleural effusion | 84 |
resistant strains | 84 |
emergency care | 84 |
randomly assigned | 84 |
randomised controlled | 84 |
life care | 84 |
published maps | 84 |
medical treatment | 84 |
vein thrombosis | 84 |
also found | 84 |
institutional affiliations | 84 |
chest tube | 84 |
old woman | 84 |
nature remains | 83 |
springer nature | 83 |
care society | 83 |
may occur | 83 |
hospital los | 83 |
healthy subjects | 83 |
severe trauma | 83 |
blood volume | 83 |
aged years | 83 |
remains neutral | 83 |
inspired oxygen | 83 |
positive pressure | 83 |
prospective randomized | 83 |
pain management | 83 |
disseminated intravascular | 83 |
hours post | 83 |
correlation coefficient | 83 |
high rate | 83 |
jurisdictional claims | 83 |
first time | 83 |
new zealand | 83 |
higher levels | 82 |
pulmonary aspergillosis | 82 |
functional outcomes | 82 |
conservative treatment | 82 |
small sample | 82 |
adverse outcomes | 82 |
healthcare system | 82 |
positive predictive | 82 |
analysis revealed | 82 |
considered significant | 82 |
artery bypass | 82 |
receiving mechanical | 82 |
median length | 81 |
reproduction number | 81 |
patients discharged | 81 |
scoring systems | 81 |
data set | 81 |
required icu | 81 |
term outcome | 81 |
twice daily | 81 |
study aims | 81 |
showed significant | 81 |
lung tissue | 81 |
days later | 81 |
may reduce | 81 |
high flow | 81 |
pulmonary complications | 81 |
results show | 80 |
susceptibility testing | 80 |
laboratory findings | 80 |
host response | 80 |
respiratory symptoms | 80 |
patients using | 80 |
worse outcomes | 80 |
acute stroke | 80 |
care doi | 80 |
well tolerated | 80 |
induced lung | 79 |
least days | 79 |
differ significantly | 79 |
unfavorable outcome | 79 |
multiple trauma | 79 |
spontaneous circulation | 79 |
trauma care | 79 |
evaluated using | 79 |
oxidative stress | 79 |
response rate | 79 |
considered statistically | 79 |
sepsis patients | 79 |
congestive heart | 79 |
pressure ventilation | 79 |
diseases society | 79 |
major surgery | 79 |
medical resources | 79 |
mean apache | 79 |
ventilator settings | 79 |
mean difference | 79 |
solid organ | 79 |
higher rates | 78 |
literature review | 78 |
blunt trauma | 78 |
two studies | 78 |
blood lactate | 78 |
tissue oxygen | 78 |
bloodstream infection | 78 |
liver function | 78 |
low risk | 78 |
days following | 78 |
intravascular coagulation | 78 |
beneficial effect | 78 |
posted september | 78 |
may increase | 78 |
refractory status | 78 |
cardiac function | 78 |
organ support | 78 |
diff erence | 78 |
nursing care | 78 |
respiratory mechanics | 78 |
academic medical | 77 |
trend towards | 77 |
outcome measure | 77 |
creatinine clearance | 77 |
continuous positive | 77 |
corticosteroid treatment | 77 |
renal dysfunction | 77 |
glucose levels | 77 |
bacterial co | 77 |
cell transplantation | 77 |
early phase | 77 |
medical patients | 77 |
may provide | 77 |
recent years | 77 |
group compared | 77 |
flow rate | 76 |
infection rates | 76 |
propensity score | 76 |
discharged home | 76 |
abdominal trauma | 76 |
protective ventilation | 76 |
chest wall | 76 |
risk stratification | 76 |
tissue oxygenation | 76 |
international guidelines | 76 |
randomized study | 76 |
lactate dehydrogenase | 76 |
patient died | 76 |
icu days | 76 |
frequently used | 76 |
delayed cerebral | 76 |
time course | 75 |
perfusion pressure | 75 |
driving pressure | 75 |
average time | 75 |
jugular vein | 75 |
plasma concentrations | 75 |
clinical variables | 75 |
cmv infection | 75 |
mcg ml | 75 |
high morbidity | 75 |
may cause | 75 |
middle cerebral | 75 |
pulmonary infection | 75 |
may require | 75 |
comatose patients | 75 |
strongly associated | 75 |
energy expenditure | 75 |
icu population | 75 |
eligible patients | 75 |
assessment method | 75 |
whitney test | 75 |
care physicians | 74 |
first case | 74 |
lung cancer | 74 |
postoperative day | 74 |
resource utilization | 74 |
early identification | 74 |
outcomes among | 74 |
clinical significance | 74 |
much higher | 74 |
patients enrolled | 74 |
inflammatory markers | 74 |
competing interests | 74 |
mean values | 74 |
oral care | 74 |
sex ratio | 74 |
well known | 73 |
skeletal muscle | 73 |
neutropenic patients | 73 |
groups according | 73 |
herd immunity | 73 |
investigate whether | 73 |
medical students | 73 |
extubation failure | 73 |
health services | 73 |
hong kong | 73 |
icu patient | 73 |
normal saline | 73 |
transcranial doppler | 73 |
improve outcomes | 73 |
prothrombin time | 73 |
care team | 73 |
magnetic resonance | 73 |
klebsiella pneumoniae | 73 |
may play | 73 |
acute appendicitis | 72 |
icu day | 72 |
assess whether | 72 |
survival rates | 72 |
external ventricular | 72 |
circulatory failure | 72 |
lung ultrasound | 72 |
six months | 72 |
bed capacity | 72 |
significant changes | 72 |
north america | 72 |
supportive care | 72 |
patients whose | 72 |
severe illness | 72 |
rank test | 72 |
influenza pneumonia | 72 |
protective effect | 71 |
ich score | 71 |
hazard ratio | 71 |
individual patient | 71 |
also associated | 71 |
med doi | 71 |
renal disease | 71 |
surgical procedure | 71 |
small number | 71 |
temperature management | 71 |
patients compared | 71 |
died within | 71 |
emergency medical | 71 |
group received | 71 |
subgroup analysis | 71 |
hospital death | 71 |
recent study | 71 |
one hour | 71 |
pulmonary arterial | 71 |
fluid administration | 70 |
primary care | 70 |
muscle weakness | 70 |
clinical deterioration | 70 |
relative risk | 70 |
diagnostic criteria | 70 |
lung volume | 70 |
carotid artery | 70 |
improve patient | 70 |
analysed using | 70 |
internal medicine | 70 |
time point | 70 |
influenza pandemic | 70 |
improved survival | 70 |
year mortality | 70 |
rankin scale | 70 |
candida auris | 70 |
treatment group | 70 |
clinical research | 70 |
studied patients | 70 |
routine use | 70 |
vena cava | 70 |
three times | 70 |
clinical examination | 70 |
neurologic outcome | 70 |
type ii | 69 |
plasma exchange | 69 |
antimicrobial treatment | 69 |
deep vein | 69 |
gram stain | 69 |
low tidal | 69 |
hemodynamic monitoring | 69 |
patient demographics | 69 |
fluid challenge | 69 |
american thoracic | 69 |
beneficial effects | 69 |
flow cytometry | 69 |
short term | 69 |
early stage | 69 |
studies suggest | 69 |
two weeks | 69 |
organ transplant | 69 |
guidelines recommend | 68 |
compartment syndrome | 68 |
laboratory tests | 68 |
arterial oxygen | 68 |
burn patients | 68 |
care hospital | 68 |
severe infections | 68 |
critical patients | 68 |
previous reports | 68 |
term mortality | 68 |
neuromuscular blocking | 68 |
coma score | 68 |
multivariable analysis | 68 |
patient age | 68 |
every patient | 68 |
stress disorder | 68 |
optimal control | 68 |
artery disease | 68 |
acute illness | 68 |
negative bacilli | 68 |
mcg kg | 68 |
least two | 68 |
mean length | 68 |
altered mental | 67 |
incidence rate | 67 |
hoc analysis | 67 |
final manuscript | 67 |
systematic reviews | 67 |
two days | 67 |
burst suppression | 67 |
average length | 67 |
treatment options | 67 |
cognitive dysfunction | 67 |
supine position | 67 |
emergency physicians | 67 |
early mobilization | 67 |
high frequency | 67 |
pneumococcal pneumonia | 67 |
significantly correlated | 67 |
traumatic stress | 67 |
care providers | 67 |
requiring intensive | 67 |
significant risk | 67 |
cytokine release | 66 |
resistant bacteria | 66 |
culture results | 66 |
prolonged icu | 66 |
early detection | 66 |
four score | 66 |
seven days | 66 |
icu treatment | 66 |
different types | 66 |
investigation results | 66 |
wilcoxon rank | 66 |
positive correlation | 66 |
one month | 66 |
postoperative pain | 66 |
severe brain | 66 |
fluid therapy | 66 |
clinical status | 66 |
previous study | 66 |
strains isolated | 66 |
case history | 66 |
crp levels | 66 |
pulmonary infiltrates | 66 |
multidisciplinary team | 66 |
minimally invasive | 66 |
candida spp | 66 |
adverse event | 65 |
high rates | 65 |
ventilator days | 65 |
laboratory data | 65 |
trauma registry | 65 |
care nurses | 65 |
hemodynamically stable | 65 |
study suggests | 65 |
chronic respiratory | 65 |
one third | 65 |
differential diagnosis | 65 |
longer duration | 65 |
clinical manifestations | 65 |
incubation period | 65 |
antimicrobial susceptibility | 65 |
several limitations | 65 |
primary objective | 65 |
venous thrombosis | 65 |
posted april | 65 |
clinical information | 65 |
wide range | 65 |
upper respiratory | 65 |
icu transfer | 65 |
written informed | 65 |
midline shift | 64 |
lactate level | 64 |
preliminary data | 64 |
coronavirus infection | 64 |
diff erent | 64 |
worse outcome | 64 |
central line | 64 |
platelet counts | 64 |
first step | 64 |
early warning | 64 |
confusion assessment | 64 |
pulse pressure | 64 |
decreased significantly | 64 |
mg ml | 64 |
respiratory virus | 64 |
infection prevention | 64 |
severe patients | 64 |
kidney function | 64 |
phase ii | 64 |
controlled study | 64 |
past medical | 64 |
eff ect | 64 |
discharged alive | 64 |
first group | 64 |
failure requiring | 64 |
pct levels | 64 |
analysis using | 64 |
disk diffusion | 64 |
thromboembolic events | 64 |
related complications | 63 |
clinical study | 63 |
broad spectrum | 63 |
diagnostic tests | 63 |
rib fractures | 63 |
plateau pressure | 63 |
right heart | 63 |
underlying diseases | 63 |
acquired infections | 63 |
patient received | 63 |
note springer | 63 |
directed therapy | 63 |
clinical suspicion | 63 |
clostridium difficile | 63 |
surface area | 63 |
clinical improvement | 63 |
increased morbidity | 63 |
artery catheter | 63 |
i trauma | 63 |
liver transplant | 63 |
limited data | 63 |
significantly improved | 63 |
first study | 63 |
disease progression | 63 |
complication rate | 63 |
cov infection | 63 |
older persons | 63 |
overall survival | 63 |
invasive procedures | 62 |
tissue injury | 62 |
communityacquired pneumonia | 62 |
defined according | 62 |
university hospitals | 62 |
adhesion molecules | 62 |
days vs | 62 |
standard care | 62 |
two years | 62 |
remaining patients | 62 |
longer icu | 62 |
within minutes | 62 |
white matter | 62 |
patient management | 62 |
patients met | 62 |
control subjects | 62 |
icp monitoring | 62 |
berlin definition | 62 |
endothelial cell | 62 |
lower risk | 62 |
venous catheters | 62 |
organ failures | 62 |
trauma centers | 62 |
antibiotic susceptibility | 62 |
associated infections | 62 |
high doses | 62 |
significant relationships | 62 |
sectional study | 62 |
information regarding | 62 |
massive transfusion | 62 |
sensitivity analysis | 62 |
acute coronary | 62 |
male patients | 62 |
predict mortality | 62 |
control groups | 61 |
death rate | 61 |
icu physicians | 61 |
study clinical | 61 |
patients years | 61 |
esophageal pressure | 61 |
plasminogen activator | 61 |
commercially available | 61 |
among icu | 61 |
respiratory samples | 61 |
deep sedation | 61 |
ventilator associated | 61 |
antiviral therapy | 61 |
surgical site | 61 |
common complication | 61 |
breathing trial | 61 |
significant morbidity | 61 |
aspiration pneumonia | 61 |
patients survived | 61 |
odds ratios | 61 |
patient days | 61 |
may represent | 61 |
another study | 61 |
acute cardiac | 61 |
care management | 61 |
candida species | 60 |
drug resistant | 60 |
type i | 60 |
among critically | 60 |
multiorgan failure | 60 |
lung function | 60 |
lung transplant | 60 |
vasopressor support | 60 |
multiplex pcr | 60 |
laboratory parameters | 60 |
burn injury | 60 |
relatively low | 60 |
reperfusion injury | 60 |
secondary outcome | 60 |
glycemic control | 60 |
bacterial meningitis | 60 |
identifi ed | 60 |
fungal infections | 60 |
studies reported | 60 |
organ injury | 60 |
dimer levels | 60 |
loading dose | 60 |
pulmonary function | 60 |
animal model | 60 |
lower extremity | 60 |
secondary analysis | 60 |
internal jugular | 60 |
will need | 60 |
university medical | 60 |
infections caused | 59 |
automated pupillometry | 59 |
patient underwent | 59 |
training program | 59 |
also recorded | 59 |
pulse oximetry | 59 |
cerebral vasospasm | 59 |
patient populations | 59 |
proportional hazards | 59 |
diffuse alveolar | 59 |
will require | 59 |
serum lactate | 59 |
china clinical | 59 |
cumulative incidence | 59 |
risk assessment | 59 |
open reduction | 59 |
data acquisition | 59 |
epithelial cells | 59 |
thrombin generation | 59 |
post hoc | 59 |
gas analysis | 59 |
american college | 59 |
infected pneumonia | 59 |
internal fixation | 59 |
real data | 59 |
cohort studies | 59 |
three cases | 59 |
care settings | 59 |
spectrum antibiotics | 58 |
major bleeding | 58 |
neural networks | 58 |
patients within | 58 |
attending physician | 58 |
healthcare providers | 58 |
national institute | 58 |
care facilities | 58 |
cox proportional | 58 |
phase i | 58 |
acquired weakness | 58 |
clinical condition | 58 |
electronic health | 58 |
chronic renal | 58 |
patient groups | 58 |
hematopoietic stem | 58 |
may benefit | 58 |
care bundle | 58 |
fatal outcome | 58 |
oxygen supply | 57 |
mixed venous | 57 |
case fatality | 57 |
income countries | 57 |
second group | 57 |
early recognition | 57 |
lombardy region | 57 |
serum sodium | 57 |
patient satisfaction | 57 |
antiretroviral therapy | 57 |
plasma concentration | 57 |
reduce mortality | 57 |
drotrecogin alfa | 57 |
day survival | 57 |
endothelial dysfunction | 57 |
gcs score | 57 |
glucose control | 57 |
tissue perfusion | 57 |
severely injured | 57 |
predictive models | 56 |
younger patients | 56 |
steady state | 56 |
observation period | 56 |
aneurysmal sah | 56 |
fluid overload | 56 |
making process | 56 |
took place | 56 |
adult intensive | 56 |
molecular weight | 56 |
early postoperative | 56 |
one patients | 56 |
venous oxygen | 56 |
factors related | 56 |
data indicate | 56 |
ml based | 56 |
proinflammatory cytokines | 56 |
intraventricular hemorrhage | 56 |
brain damage | 56 |
better outcome | 56 |
hospitalised patients | 56 |
hospitalized covid | 56 |
staff members | 56 |
predict fluid | 56 |
lung ventilation | 56 |
growth factor | 56 |
sum test | 56 |
fluid management | 56 |
charlson comorbidity | 56 |
national health | 56 |
antiviral treatment | 56 |
hours later | 56 |
health systems | 55 |
attending physicians | 55 |
chi square | 55 |
chest radiography | 55 |
study performed | 55 |
drug administration | 55 |
comorbidity index | 55 |
neurological complications | 55 |
within one | 55 |
study groups | 55 |
single centre | 55 |
heart surgery | 55 |
nasopharyngeal swab | 55 |
data obtained | 55 |
nan doi | 55 |
failure due | 55 |
significantly greater | 55 |
diagnostic accuracy | 55 |
medical resource | 55 |
neurological outcomes | 55 |
resistant pathogens | 55 |
palliative approach | 55 |
suspected infection | 55 |
male sex | 55 |
organ dysfunctions | 55 |
classified according | 55 |
empirical antibiotic | 55 |
treatment failure | 55 |
clinical diagnosis | 55 |
lpv cds | 55 |
ich volume | 54 |
also observed | 54 |
diabetic patients | 54 |
neural network | 54 |
lung resection | 54 |
frozen plasma | 54 |
apache iii | 54 |
placebo group | 54 |
potential risk | 54 |
hematoma expansion | 54 |
activated protein | 54 |
animal studies | 54 |
may reflect | 54 |
care center | 54 |
four groups | 54 |
study using | 54 |
several factors | 54 |
clinical symptoms | 54 |
respiratory muscle | 54 |
pain scores | 54 |
resonance imaging | 54 |
also significantly | 54 |
influenza patients | 54 |
urinary antigen | 54 |
positive results | 54 |
closely related | 54 |
statistical difference | 54 |
unfractionated heparin | 54 |
international congresses | 54 |
beds per | 54 |
better understand | 54 |
non invasive | 54 |
clinical parameters | 54 |
patients reported | 53 |
future research | 53 |
hospital stays | 53 |
selection bias | 53 |
related mortality | 53 |
patients developing | 53 |
fl ow | 53 |
regression analyses | 53 |
defi ned | 53 |
serum concentrations | 53 |
jugular bulb | 53 |
asah patients | 53 |
acute liver | 53 |
ct findings | 53 |
adult respiratory | 53 |
well established | 53 |
covid patients | 53 |
risk group | 53 |
results showed | 53 |
financial support | 53 |
tissue damage | 53 |
tube placement | 53 |
require icu | 53 |
care professionals | 53 |
systolic function | 53 |
per minute | 53 |
mechanical ventilator | 53 |
inotropic support | 53 |
troponin i | 53 |
niv failure | 53 |
opportunistic infections | 53 |
three months | 53 |
clinical setting | 53 |
cardiovascular diseases | 52 |
single dose | 52 |
effective treatment | 52 |
chronic lung | 52 |
data will | 52 |
least hours | 52 |
developing countries | 52 |
invasive pulmonary | 52 |
remained unchanged | 52 |
hepatic failure | 52 |
wistar rats | 52 |
minute ventilation | 52 |
neuro icu | 52 |
consensus statement | 52 |
normal values | 52 |
clinical criteria | 52 |
previously healthy | 52 |
mg day | 52 |
predicted mortality | 52 |
respiratory secretions | 52 |
data show | 52 |
elevated icp | 52 |
health status | 52 |
adult inpatients | 52 |
significantly longer | 52 |
weight heparin | 52 |
care resources | 52 |
diagnostic testing | 52 |
therapeutic anticoagulation | 52 |
among hospitalized | 52 |
care syndrome | 52 |
cds tool | 52 |
hospital acquired | 52 |
results obtained | 52 |
gastrointestinal tract | 52 |
patients often | 52 |
decision support | 51 |
mean value | 51 |
using standard | 51 |
tracheostomy tube | 51 |
second wave | 51 |
chronic liver | 51 |
patient group | 51 |
every day | 51 |
risk score | 51 |
blocking agents | 51 |
tested positive | 51 |
cardiac failure | 51 |
inspiratory pressure | 51 |
fisher exact | 51 |
high number | 51 |
acute pulmonary | 51 |
daily living | 51 |
tertiary referral | 51 |
ventilator support | 51 |
cytokine production | 51 |
distancing measures | 51 |
better outcomes | 51 |
bed icu | 51 |
care beds | 51 |
low levels | 51 |
american society | 51 |
herpes simplex | 51 |
foreign body | 51 |
pressure monitoring | 51 |
control patients | 51 |
may explain | 51 |
unit admission | 51 |
respiratory diseases | 51 |
vasoactive drugs | 51 |
inferior vena | 51 |
outcomes included | 51 |
published data | 51 |
severe hypoxemia | 51 |
type diabetes | 51 |
may develop | 51 |
consecutive adult | 51 |
cervical spine | 51 |
hospital survival | 50 |
first three | 50 |
liver cirrhosis | 50 |
pk pd | 50 |
daily basis | 50 |
gestational age | 50 |
injury patients | 50 |
abdominal wall | 50 |
previously published | 50 |
blood transfusions | 50 |
ill adult | 50 |
monoclonal antibodies | 50 |
ventricular fibrillation | 50 |
patients experienced | 50 |
level trauma | 50 |
infl ammatory | 50 |
thrombotic complications | 50 |
prospectively studied | 50 |
currently available | 50 |
target temperature | 50 |
prospective multicenter | 50 |
insulin therapy | 50 |
receive either | 50 |
mortality due | 50 |
fresh frozen | 50 |
icu delirium | 50 |
median icu | 50 |
paediatric intensive | 50 |
kg hr | 50 |
general ward | 50 |
remains controversial | 50 |
two hours | 50 |
chest radiographs | 50 |
increased incidence | 50 |
therapeutic intervention | 50 |
sepsis syndrome | 50 |
multicenter cohort | 50 |
clavulanic acid | 50 |
patients require | 50 |
confounding factors | 50 |
care hospitals | 50 |
term survival | 50 |
secondary endpoints | 49 |
virus disease | 49 |
first dose | 49 |
cardiac surgical | 49 |
statistically different | 49 |
cardiac arrests | 49 |
icu death | 49 |
vte prophylaxis | 49 |
newly developed | 49 |
converting enzyme | 49 |
cox regression | 49 |
disease patients | 49 |
patients suffered | 49 |
posttraumatic stress | 49 |
standard deviations | 49 |
county level | 49 |
lopinavir ritonavir | 49 |
alveolar damage | 49 |
similar results | 49 |
following criteria | 49 |
mdr pathogens | 49 |
infl uenza | 49 |
mechanical ventilators | 49 |
identified using | 49 |
acute exacerbation | 49 |
care nursing | 49 |
group showed | 49 |
healthcare systems | 49 |
new onset | 49 |
using data | 49 |
better understanding | 49 |
body surface | 49 |
birth weight | 49 |
bypass grafting | 49 |
ct head | 49 |
icu support | 49 |
continuous eeg | 49 |
clinical care | 49 |
red cell | 49 |
antifungal therapy | 49 |
rescue therapy | 49 |
receptor antagonist | 49 |
conducted using | 49 |
eff ects | 49 |
acute hypoxemic | 49 |
hemodynamic stability | 49 |
clinical progression | 48 |
hospital care | 48 |
negative staphylococci | 48 |
feeding tube | 48 |
cell death | 48 |
worse prognosis | 48 |
resource use | 48 |
severe forms | 48 |
empiric therapy | 48 |
muscle mass | 48 |
serum samples | 48 |
immune cells | 48 |
quality control | 48 |
term care | 48 |
false positive | 48 |
cerebral infarction | 48 |
comorbid conditions | 48 |
potential role | 48 |
organ function | 48 |
severe infection | 48 |
recent data | 48 |
lung compliance | 48 |
cd cd | 48 |
admission rate | 48 |
patient developed | 48 |
decompressive craniectomy | 48 |
following parameters | 48 |
center retrospective | 48 |
average number | 48 |
arterial lactate | 48 |
successful weaning | 48 |
higher level | 48 |
tissue hypoxia | 48 |
ml cmh | 48 |
times higher | 48 |
antiviral drugs | 48 |
congenital heart | 48 |
significantly elevated | 48 |
data available | 48 |
per hour | 48 |
patients due | 48 |
ex vivo | 48 |
undergoing cardiac | 48 |
done using | 48 |
organ system | 48 |
authors concluded | 48 |
march th | 48 |
damage control | 48 |
multivariate regression | 48 |
performance status | 48 |
prospectively enrolled | 48 |
rater reliability | 48 |
secondary bacterial | 48 |
also reported | 48 |
month mortality | 48 |
gastrointestinal bleeding | 47 |
epidemiological characteristics | 47 |
may influence | 47 |
will also | 47 |
cerebrovascular disease | 47 |
vast majority | 47 |
antibiotic prophylaxis | 47 |
vap rates | 47 |
reduced mortality | 47 |
clinical experience | 47 |
clinical severity | 47 |
serious complications | 47 |
preventive measures | 47 |
human metapneumovirus | 47 |
twelve patients | 47 |
ecmo support | 47 |
optic nerve | 47 |
inspiratory flow | 47 |
using spss | 47 |
coagulation parameters | 47 |
york city | 47 |
investigated whether | 47 |
hospital setting | 47 |
ventricular drain | 47 |
urinary catheter | 47 |
improved outcomes | 47 |
therapeutic interventions | 47 |
adverse drug | 47 |
evaluate whether | 47 |
gel electrophoresis | 47 |
platelet transfusion | 47 |
survival time | 47 |
bleeding complications | 47 |
ppe use | 47 |
hospital course | 47 |
influenza season | 47 |
icu occupancy | 47 |
many countries | 47 |
arterial hypertension | 47 |
variables associated | 47 |
bal fluid | 47 |
readily available | 47 |
evidence suggests | 47 |
supplemental oxygen | 46 |
base excess | 46 |
cognitive interventions | 46 |
invasive fungal | 46 |
renal impairment | 46 |
practice guideline | 46 |
median value | 46 |
corresponding author | 46 |
team members | 46 |
poor neurological | 46 |
european countries | 46 |
total body | 46 |
respiratory therapists | 46 |
high sensitivity | 46 |
significant impact | 46 |
often used | 46 |
negative patients | 46 |
rank sum | 46 |
stenotrophomonas maltophilia | 46 |
hospital ward | 46 |
respiratory function | 46 |
recently published | 46 |
controlled ventilation | 46 |
predicted body | 46 |
elevated levels | 46 |
identify factors | 46 |
days mortality | 46 |
serious adverse | 46 |
usual care | 46 |
patients needed | 46 |
icu data | 46 |
increased levels | 46 |
external fixation | 46 |
neurological recovery | 46 |
using chi | 46 |
pilot rct | 46 |
dysfunction syndrome | 46 |
apache score | 46 |
severe coronavirus | 46 |
lung water | 46 |
anticancer therapy | 46 |
infrared spectroscopy | 46 |
partial thromboplastin | 46 |
candida albicans | 46 |
standard therapy | 46 |
using two | 46 |
clinical conditions | 46 |
medical school | 45 |
increasing number | 45 |
following cardiac | 45 |
radial head | 45 |
femoral artery | 45 |
ideal body | 45 |
per group | 45 |
without significant | 45 |
propofol infusion | 45 |
retrospectively analyzed | 45 |
cardiac troponin | 45 |
month follow | 45 |
high quality | 45 |
wound infection | 45 |
icu management | 45 |
group versus | 45 |
common pathogens | 45 |
severity index | 45 |
clinical use | 45 |
subgroup analyses | 45 |
care department | 45 |
smooth muscle | 45 |
visual inspection | 45 |
deceased patients | 45 |
literature search | 45 |
chest compressions | 45 |
host defense | 45 |
female patients | 45 |
posted october | 45 |
two independent | 45 |
diff erences | 45 |
study patients | 45 |
admission diagnosis | 45 |
care capacity | 45 |
air pollution | 45 |
data showed | 45 |
respiratory insufficiency | 45 |
median days | 45 |
positive cultures | 45 |
neuromuscular blockers | 45 |
resistant isolates | 45 |
prognostic factor | 45 |
complication rates | 45 |
often associated | 45 |
subdural hematoma | 45 |
continuous data | 45 |
wound healing | 45 |
hospital admissions | 45 |
fungal infection | 45 |
improve survival | 45 |
retrospective case | 45 |
human immunodeficiency | 45 |
volume expansion | 44 |
identifying patients | 44 |
lavage fluid | 44 |
negative correlation | 44 |
failure rate | 44 |
hemorrhagic stroke | 44 |
trauma surgery | 44 |
thoracic trauma | 44 |
health professionals | 44 |
pcr assay | 44 |
early treatment | 44 |
general intensive | 44 |
initial treatment | 44 |
immune function | 44 |
influenza vaccination | 44 |
randomly selected | 44 |
new cases | 44 |
major role | 44 |
clinical impact | 44 |
monoclonal antibody | 44 |
predictive model | 44 |
resistance genes | 44 |
brain dysfunction | 44 |
good neurological | 44 |
also collected | 44 |
trend toward | 44 |
icu resources | 44 |
core temperature | 44 |
continuous monitoring | 44 |
children admitted | 44 |
treatment groups | 44 |
young children | 44 |
neurological examination | 44 |
life expectancy | 44 |
research ethics | 44 |
diffusion method | 44 |
acutely ill | 44 |
repeated measures | 44 |
cost per | 44 |
cardiac dysfunction | 44 |
higher proportion | 44 |
iu ml | 44 |
study demonstrated | 44 |
year study | 44 |
natriuretic peptide | 44 |
different levels | 44 |
immune responses | 44 |
related infections | 44 |
ed visit | 44 |
resource allocation | 44 |
study will | 44 |
sepsis septic | 43 |
standard treatment | 43 |
will help | 43 |
organ damage | 43 |
abcdef bundle | 43 |
months post | 43 |
medical university | 43 |
post operative | 43 |
past years | 43 |
amino acid | 43 |
general wards | 43 |
treatment strategies | 43 |
artificial intelligence | 43 |
rbc transfusion | 43 |
many studies | 43 |
met inclusion | 43 |
potential confounders | 43 |
cuff pressure | 43 |
roc curves | 43 |
individual patients | 43 |
significantly shorter | 43 |
antibiotic administration | 43 |
main results | 43 |
health record | 43 |
influenza viruses | 43 |
saps score | 43 |
limited number | 43 |
rapid response | 43 |
surgical management | 43 |
south africa | 43 |
adjunctive therapy | 43 |
medical centers | 43 |
lumbar puncture | 43 |
study date | 43 |
group iii | 43 |
laboratory values | 43 |
seasonal influenza | 43 |
large cohort | 43 |
information system | 43 |
mechanical power | 43 |
useful tool | 43 |
routinely used | 43 |
following icu | 43 |
survival analysis | 43 |
final version | 43 |
adult icus | 43 |
weight loss | 43 |
study found | 43 |
function tests | 43 |
inhaled nitric | 43 |
inflammatory responses | 43 |
fatty acids | 43 |
main cause | 43 |
pupillary light | 43 |
factors may | 43 |
convenience sample | 43 |
ethical committee | 43 |
younger age | 43 |
altman analysis | 43 |
available resources | 43 |
brain edema | 43 |
inhospital mortality | 43 |
oxygen extraction | 43 |
patients according | 43 |
neurointensive care | 43 |
clinical factors | 43 |
drug interactions | 43 |
life threatening | 43 |
serum albumin | 43 |
current practice | 43 |
cytokine levels | 43 |
transpulmonary thermodilution | 43 |
april th | 43 |
pneumonia caused | 43 |
cerebral performance | 43 |
difficult airway | 42 |
may affect | 42 |
undergoing elective | 42 |
ebola virus | 42 |
average duration | 42 |
ali ards | 42 |
respiratory illness | 42 |
log cfu | 42 |
mortality associated | 42 |
lung biopsy | 42 |
significant predictors | 42 |
rat model | 42 |
authors read | 42 |
mainly due | 42 |
thromboplastin time | 42 |
poor functional | 42 |
hours following | 42 |
ethics approval | 42 |
favorable outcome | 42 |
spontaneous ich | 42 |
south korea | 42 |
clinical response | 42 |
pleural fluid | 42 |
hospital icu | 42 |
patients following | 42 |
discharge disposition | 42 |
end point | 42 |
results demonstrate | 42 |
specific treatment | 42 |
day post | 42 |
mononuclear cells | 42 |
strong recommendation | 42 |
higher apache | 42 |
vascular permeability | 42 |
independent variables | 42 |
interval ci | 42 |
significant higher | 42 |
attributable mortality | 42 |
mortality compared | 42 |
treated group | 42 |
screening tool | 42 |
immunodeficiency virus | 42 |
flow velocity | 42 |
brain trauma | 42 |
significant change | 42 |
kidney failure | 42 |
positive culture | 42 |
risk groups | 42 |
less frequently | 42 |
patient ratio | 42 |
study demonstrates | 42 |
consensus conference | 42 |
group vs | 42 |
hematoma volume | 42 |
dose thromboprophylaxis | 42 |
vascular injury | 42 |
neuraminidase inhibitors | 42 |
clinical evaluation | 42 |
systemic vascular | 42 |
clinical settings | 41 |
mic values | 41 |
group patients | 41 |
way anova | 41 |
time series | 41 |
resistant organisms | 41 |
postoperative course | 41 |
good clinical | 41 |
spectrum beta | 41 |
days prior | 41 |
blood oxygen | 41 |
cant diff | 41 |
secondary infections | 41 |
related organ | 41 |
antimicrobial stewardship | 41 |
initial management | 41 |
grade iii | 41 |
five days | 41 |
patients older | 41 |
diagnostic yield | 41 |
clinical samples | 41 |
two methods | 41 |
prior studies | 41 |
plasma samples | 41 |
cases per | 41 |
social media | 41 |
categorical data | 41 |
patients per | 41 |
first year | 41 |
year survival | 41 |
bacterial growth | 41 |
transthoracic echocardiography | 41 |
less severe | 41 |
blood components | 41 |
factors influencing | 41 |
comparative study | 41 |
may need | 41 |
higher prevalence | 41 |
children aged | 41 |
mathematical model | 41 |
complications associated | 41 |
another hospital | 41 |
studies showed | 41 |
sirs criteria | 41 |
remains unknown | 41 |
mass casualty | 41 |
hospital wards | 41 |
ward patients | 41 |
significantly less | 41 |
unstable patients | 41 |
esrd patients | 41 |
healthy control | 41 |
cognitive function | 41 |
total patients | 41 |
intensive insulin | 41 |
baseline values | 41 |
severe outcomes | 41 |
expert opinion | 40 |
primary outcomes | 40 |
hospital day | 40 |
low molecular | 40 |
recombinant human | 40 |
treatment duration | 40 |
surgical tracheostomy | 40 |
nutritional status | 40 |
patients ventilated | 40 |
electrical activity | 40 |
treat patients | 40 |
ventilation time | 40 |
data suggests | 40 |
within months | 40 |
spontaneously breathing | 40 |
oxygen desaturation | 40 |
obtained using | 40 |
icp mmhg | 40 |
gut microbiota | 40 |
common causes | 40 |
significant proportion | 40 |
therapeutic management | 40 |
received tocilizumab | 40 |
dawley rats | 40 |
kcal kg | 40 |
renal insufficiency | 40 |
may present | 40 |
volume ventilation | 40 |
important factor | 40 |
mean icu | 40 |
mg twice | 40 |
main outcome | 40 |
bypass surgery | 40 |
penetrating trauma | 40 |
lung diseases | 40 |
mean number | 40 |
induced thrombocytopenia | 40 |
medical management | 40 |
blood product | 40 |
experimental study | 40 |
splenic injury | 40 |
relatively high | 40 |
multicenter prospective | 40 |
extravascular lung | 40 |
good functional | 40 |
first line | 40 |
intramedullary nailing | 40 |
will likely | 40 |
hematologic malignancies | 40 |
insulin infusion | 40 |
pneumonia severity | 40 |
septic complications | 40 |
less common | 40 |
also showed | 40 |
physical therapy | 40 |
ug ml | 40 |
different groups | 40 |
existing kidney | 40 |
hours prior | 40 |
low flow | 40 |
appropriate treatment | 40 |
icu hospitalization | 40 |
positive cocci | 39 |
immunocompetent patients | 39 |
study reported | 39 |
oxygen tension | 39 |
tracheal aspirates | 39 |
sodium chloride | 39 |
one day | 39 |
high degree | 39 |
common among | 39 |
internal carotid | 39 |
potential benefits | 39 |
longer time | 39 |
significance level | 39 |
major abdominal | 39 |
important cause | 39 |
sensitivity analyses | 39 |
epidemiological data | 39 |
positive test | 39 |
global health | 39 |
shockable rhythm | 39 |
coronary angiography | 39 |
study cohort | 39 |
antibiotic prescription | 39 |
male gender | 39 |
virus infections | 39 |
abdominal sepsis | 39 |
avian influenza | 39 |
severe complications | 39 |
qualitative data | 39 |
postoperative care | 39 |
ml vs | 39 |
per cent | 39 |
cell surface | 39 |
lower incidence | 39 |
resistant gram | 39 |
fi ndings | 39 |
per se | 39 |
overall incidence | 39 |
pulmonary oedema | 39 |
empirical treatment | 39 |
ventilatorassociated pneumonia | 39 |
four different | 39 |
studies included | 39 |
per week | 39 |
bacterial translocation | 39 |
increasing age | 39 |
urine samples | 39 |
nucleic acid | 39 |
neurosurgical patients | 39 |
burned patients | 39 |
clinical assessment | 39 |
blood stream | 39 |
hemodynamically unstable | 39 |
blood count | 39 |
cirrhotic patients | 39 |
northern italy | 39 |
ill icu | 39 |
studies using | 39 |
postoperative delirium | 39 |
femoral neck | 39 |
pediatric icu | 39 |
early mortality | 39 |
first patient | 39 |
cardiopulmonary arrest | 39 |
likely due | 39 |
fold increase | 39 |
patient presented | 39 |
simplex virus | 39 |
left ventricle | 39 |
good correlation | 39 |
muscle strength | 39 |
therapy may | 39 |
one hand | 39 |
likert scale | 39 |
included age | 39 |
hepatic encephalopathy | 39 |
upper limit | 39 |
also performed | 39 |
amino acids | 39 |
multicentre study | 39 |
highly significant | 39 |
stable patients | 38 |
cytomegalovirus infection | 38 |
upper airway | 38 |
patient selection | 38 |
coronary syndrome | 38 |
nitrogen balance | 38 |
medical surgical | 38 |
patient admitted | 38 |
pneumonia patients | 38 |
bacterial pathogens | 38 |
emergency response | 38 |
transmission dynamics | 38 |
intellectual content | 38 |
demographic information | 38 |
identify risk | 38 |
empiric antibiotic | 38 |
onset vap | 38 |
final diagnosis | 38 |
advanced age | 38 |
targeted temperature | 38 |
complications related | 38 |
among survivors | 38 |
related quality | 38 |
months later | 38 |
initial dose | 38 |
poorly understood | 38 |
consecutive days | 38 |
expiratory flow | 38 |
recently reported | 38 |
vascular access | 38 |
generating procedures | 38 |
idsa ats | 38 |
first report | 38 |
care systems | 38 |
binding protein | 38 |
total parenteral | 38 |
study also | 38 |
release syndrome | 38 |
cell transplant | 38 |
statistical methods | 38 |
developed acute | 38 |
received antibiotics | 38 |
creatine kinase | 38 |
large proportion | 38 |
warning score | 38 |
ace inhibitors | 38 |
linear mixed | 38 |
bacterial sepsis | 38 |
median number | 38 |
chest trauma | 38 |
bacterial resistance | 38 |
reported cases | 38 |
major complications | 38 |
admission gcs | 38 |
developed ards | 38 |
infusion rate | 38 |
four hours | 38 |
low level | 38 |
health problem | 38 |
clinical picture | 38 |
small intestine | 38 |
performance category | 38 |
vitro activity | 38 |
higher doses | 38 |
acinetobacter spp | 38 |
portal vein | 38 |
reactive oxygen | 38 |
dead space | 38 |
icu liberation | 38 |
bacterial coinfection | 38 |
depression scale | 38 |
control practices | 38 |
early stages | 38 |
neurological injury | 38 |
ketamine infusion | 38 |
stage renal | 38 |
time periods | 38 |
cardiac disease | 37 |
icu cases | 37 |
years ago | 37 |
lower extremities | 37 |
high volume | 37 |
fold higher | 37 |
group without | 37 |
differed significantly | 37 |
mortality prediction | 37 |
patients affected | 37 |
open lung | 37 |
associated injuries | 37 |
remained stable | 37 |
french icus | 37 |
extracorporeal life | 37 |
upper extremity | 37 |
glucose level | 37 |
decreased mortality | 37 |
medical therapy | 37 |
secondary infection | 37 |
pharmaceutical interventions | 37 |
iu kg | 37 |
week period | 37 |
complement activation | 37 |
infection may | 37 |
ventilated icu | 37 |
early use | 37 |
million people | 37 |
weaning failure | 37 |
higher percentage | 37 |
much lower | 37 |
case mix | 37 |
received either | 37 |
term follow | 37 |
vegetative state | 37 |
medical team | 37 |
intravenous infusion | 37 |
data extraction | 37 |
light reflex | 37 |
right atrium | 37 |
motor vehicle | 37 |
filtration rate | 37 |
hip fracture | 37 |
alcohol abuse | 37 |
therapeutic options | 37 |
deep venous | 37 |
lymphocyte counts | 37 |
traumatic injury | 37 |
pulse contour | 37 |
bactericidal activity | 37 |
care facility | 37 |
neurological deficits | 37 |
current guidelines | 37 |
underlying medical | 37 |
brain mri | 37 |
several days | 37 |
sedation scale | 37 |
community hospital | 37 |
th percentile | 37 |
controlled clinical | 37 |
right ventricle | 37 |
patients transferred | 37 |
may include | 37 |
ethical approval | 37 |
required invasive | 37 |
mean icp | 37 |
young adults | 37 |
chronic pain | 37 |
lung protective | 37 |
critical ill | 37 |
serum glucose | 37 |
ventricular function | 37 |
may decrease | 37 |
early administration | 37 |
square tests | 37 |
medical services | 37 |
longer hospital | 37 |
dysfunction failure | 37 |
eeg monitoring | 36 |
main causes | 36 |
interim guidance | 36 |
higher among | 36 |
clinical benefit | 36 |
prior antibiotic | 36 |
polymicrobial aetiology | 36 |
preliminary study | 36 |
significantly better | 36 |
family satisfaction | 36 |
pain score | 36 |
respiratory viral | 36 |
higher number | 36 |
time frame | 36 |
interquartile ranges | 36 |
confirmed case | 36 |
health emergency | 36 |
examination revealed | 36 |
also evaluated | 36 |
intermediate care | 36 |
glass opacities | 36 |
adverse outcome | 36 |
medical education | 36 |
increased icu | 36 |
characteristic curve | 36 |
care admission | 36 |
thrombolytic therapy | 36 |
cystic fibrosis | 36 |
health workers | 36 |
venous access | 36 |
based study | 36 |
probably due | 36 |
requiring hospitalization | 36 |
sedated patients | 36 |
respiratory complications | 36 |
undergoing thoracic | 36 |
increasingly used | 36 |
received mechanical | 36 |
transpulmonary pressure | 36 |
multiple logistic | 36 |
ulcer prophylaxis | 36 |
medical research | 36 |
hess grade | 36 |
pearson correlation | 36 |
elective cardiac | 36 |
ventilation duration | 36 |
fracture healing | 36 |
richmond agitation | 36 |
rating scale | 36 |
early tracheostomy | 36 |
improves survival | 36 |
developed severe | 36 |
twenty patients | 36 |
trauma team | 36 |